Results 321 to 330 of about 12,469,641 (375)

Visceral fat area loss reduces 10-year atherosclerotic cardiovascular disease risk in Chinese population with type 2 diabetes mellitus: a prospective cohort study. [PDF]

Lipids Health Dis
Jin J, Lei Y, Zheng J, Xu J, Chen L, Liu S, Cao X, Hu Y, Yan C, Wu X.   +9 more
europepmc   +1 more source

Revealing sex-specific changes across protein structure in the aging bone extracellular matrix. [PDF]

Matrix Biol Plus
Tudor J, Eckersley A, Buckley M.
europepmc   +1 more source

Associations of lipoprotein subclasses with all-cause and cardiovascular mortality: results of two independent cohorts with a 20 year follow-up. [PDF]

Lipids Health Dis
Fierfas F, Bahls M, Henning AK, Petersmann A, Budde K, Dörr M, Völzke H, Nauck M, Hannemann A, Friedrich N.   +9 more
europepmc   +1 more source

Hypobetalipoproteinaemia and truncated forms of human apolipoprotein B

, 1992
Sally Priscilla Anna McCormick
openalex   +1 more source

Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B.

, 1991
Prescott Mf, McBride Ch, Judith Hasler‐Rapacz, Von Linden J, J. Rapacz   +4 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Update on apolipoprotein B

Current Opinion in Lipidology, 2021
Purpose of review The 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines concluded that apolipoprotein B (apoB) was a more accurate measure of cardiovascular risk and a better guide to the adequacy of lipid lowering than low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein ...
Sniderman, A., Langlois, M., Cobbaert, C.   +2 more
openaire   +3 more sources

Apolipoprotein A1 and B

Clinics in Laboratory Medicine, 2006
This article reviews the evidence showing that apolipoprotein (apo) B and A-1 are superior to the conventional cholesterol indices as analytes in laboratory practice, indices of the lipoprotein-related risk for vascular disease, and measures of the adequacy of low-density lipoprotein-lowering therapy.
Allan D, Sniderman, Santica M, Marcovina
openaire   +2 more sources

Apolipoprotein B synthesis in humans: Liver synthesizes only apolipoprotein B-100

Metabolism, 1985
Apolipoprotein (apo) B-100 and B-48 are prominent apolipoproteins in VLDL, IDL, and chylomicrons. Organ cultures of normal adult human liver were established to ascertain the form of apo B synthesized by hepatocytes in humans. Human liver was minced and incubated in 15 mL methionine-free RPMI-1640 medium with 10% dialyzed fetal calf serum plus 250 ...
S B, Edge, J M, Hoeg, P D, Schneider, H B, Brewer   +3 more
openaire   +2 more sources

Apolipoprotein B polymorphism and altered apolipoprotein B concentrations in Congolese blacks

Clinical Genetics, 1991
The immunoreactivity of apolipoprotein B (apo B) in plasma obtained from 238 unrelated black African male subjects from the People's Republic of Congo was analysed by non‐competitive Enzyme Linked‐Immunosorbent Assay (ELISA) with monoclonal BIP 45 anti‐LDL antibody.
H J, Parra, F, Martin, F, Monard, N, Ngangoué, N, Copin, J M, Bard, M, Qafli, N, Vu Dac, P, Duriez, J C, Fruchart   +9 more
openaire   +2 more sources

Rat apolipoprotein B differs in solubility properties from human apolipoprotein B

Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
Apolipoprotein B (ApoB) in general is known as an insoluble protein in aqueous buffers without the initial aid of denaturing agents. However, following the total delipidization of rat plasma low-density lipoproteins, a considerable portion (28.2 +/- 3.0%) of rat ApoB was found directly soluble in an aqueous buffer, N-ethylmorpholine acetate (pH 7.3) as
V S, Kamanna, D L, Stiers, D M, Lee
openaire   +2 more sources